Výsledky vyhledávání - Lars Endahl

  • Zobrazuji výsledky 1 - 11 z 11
Upřesnit hledání
  1. 1
    Superior glycaemic control with once‐daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial

    Superior glycaemic control with once‐daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs:... Autor Yukiko Onishi, Yasuhiro Ono, Rasmus Rabøl, Lars Endahl, S. Nakamura

    Vydáno 2013
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Lower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in People With Type 1 Diabetes

    Lower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in People With Type 1 Diabetes Autor Tim Heise, Leszek Nosek, Birgitte Rønn, Lars Endahl, Lutz Heinemann, Christoph Kapitza, Eberhard Draeger

    Vydáno 2004
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  3. 3
    Treatment intensification with an insulin degludec (<scp>IDeg</scp>)/insulin aspart (<scp>IAsp</scp>) co‐formulation twice daily compared with basal <scp>IDeg</scp> and prandial <scp>IAsp</scp> in type 2 diabetes: a randomized, controlled phase <scp>III</scp> trial

    Treatment intensification with an insulin degludec (<scp>IDeg</scp>)/insulin aspart (<scp>IAsp</scp>) co‐formulation twice daily compared with basal <scp>IDeg</scp> and prandial <s... Autor Helena W. Rodbard, Bertrand Cariou, Thomas R. Pieber, Lars Endahl, Jeppe Zacho, John Graham Cooper

    Vydáno 2015
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Efficacy and safety of once‐daily insulin degludec/insulin aspart compared with once‐daily insulin glargine in participants with Type 2 diabetes: a randomized, treat‐to‐target study

    Efficacy and safety of once‐daily insulin degludec/insulin aspart compared with once‐daily insulin glargine in participants with Type 2 diabetes: a randomized, treat‐to‐target stud... Autor Sudhesh Kumar, Hak Chul Jang, Nilgün Güvener Demirağ, Trine Vang Skjøth, Lars Endahl, Bruce W. Bode

    Vydáno 2016
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  5. 5
    Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity

    Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity Autor Martin Friedrichsen, Lars Endahl, Frederik Flindt Kreiner, Ronald Goldwater, Martin Kankam, Søren Toubro, Sune Boris Nygård

    Vydáno 2023
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes

    Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes Autor Bernard Zinman, Athena Philis‐Tsimikas, Bertrand Cariou, Yehuda Handelsman, Helena W. Rodbard, Thue Johansen, Lars Endahl, Chantal Mathieu

    Vydáno 2012
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  7. 7
    Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre‐planned meta‐analysis of phase 3 trials

    Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre‐planned meta‐analysis of phase 3 trials Autor Robert E. Ratner, Stephanie Gough, Chantal Mathieu, Stefano Del Prato, Bruce W. Bode, Henriette Mersebach, Lars Endahl, Bernard Zinman

    Vydáno 2012
    Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  8. 8
    Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data

    Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data Autor Sean Wharton, Arne Astrup, Lars Endahl, Michael E. J. Lean, Altynai Satylganova, Dorthe Skovgaard, Thomas A. Wadden, John Wilding

    Vydáno 2021
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  9. 9
    A Double-Blind, Randomized, Dose-Response Study Investigating the Pharmacodynamic and Pharmacokinetic Properties of the Long-Acting Insulin Analog Detemir

    A Double-Blind, Randomized, Dose-Response Study Investigating the Pharmacodynamic and Pharmacokinetic Properties of the Long-Acting Insulin Analog Detemir Autor Johannes Plank, Manfred Bodenlenz, Frank Sinner, Christoph Magnes, Evelyn Görzer, Werner Regittnig, Lars Endahl, Eberhard Draeger, Milan Zdravkovic, Thomas R. Pieber

    Vydáno 2005
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  10. 10
    Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial

    Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial Autor Leo Niskanen, Lawrence A. Leiter, Edward Franek, Jianping Weng, Taner Damcı, Manuel Muñoz‐Torres, Jean-Paul Donnet, Lars Endahl, Trine Vang Skjøth, Allan Vaag

    Vydáno 2012
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  11. 11
    Insulin Degludec in Type 1 Diabetes

    Insulin Degludec in Type 1 Diabetes Autor Kåre I. Birkeland, Philip Home, Ulrich Wendisch, Robert E. Ratner, Thue Johansen, Lars Endahl, Karsten Lyby, Johan Jendle, Anthony P. Roberts, J. Hans DeVries, Luigi Meneghini

    Vydáno 2011
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: